Literature DB >> 16354984

Ballantyne syndrome: a case report.

Delia M Paternoster1, Francesca Manganelli, Daria Minucci, Kimta Ngaradoumbe Nanhornguè, Alessia Memmo, Margherita Bertoldini, Umberto Nicolini.   

Abstract

Ballantyne syndrome (also called mirror syndrome or triple edema) describes the unusual association of fetal and placental hydrops with maternal preeclampsia. This is a case report illustrating a 37-year-old patient who was referred to our clinics at 28 weeks of gestation (wg) because of fetal hydrothorax. On examination, the woman did not show signs of preeclampsia. The fetal ultrasound examination revealed bulky hydrothorax, generalized subcutaneous edema, placental edema, and polyhydramnios. It was not possible to find the cause of the fetal hydrops. At 29 weeks and 4 days of gestation, the fetal hydrothorax was removed by two pleuro-amniotic shunts, but at the moment of our intervention anasarca was already present. In the following 3 days, despite observing bed rest, the mother developed edema of hands and face, while blood pressure remained normal. At 30 wg the patient underwent cesarean section because fetal movements ceased and the fetal heart rate monitoring showed loss of variability and decelerations. Before dying, the neonate lived for 20 days in a state of deep hypotension. (c) 2006 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2006        PMID: 16354984     DOI: 10.1159/000089056

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

1.  Changes in echocardiography and blood variables during and after development of Ballantyne syndrome.

Authors:  Takeshi Umazume; Mamoru Morikawa; Takahiro Yamada; Hisanori Minakami
Journal:  BMJ Case Rep       Date:  2016-06-21

2.  Resolution of maternal Mirror syndrome after succesful fetal intrauterine therapy: a case series.

Authors:  Angel Chimenea; Lutgardo García-Díaz; Ana María Calderón; María Moreno-De Las Heras; Guillermo Antiñolo
Journal:  BMC Pregnancy Childbirth       Date:  2018-04-06       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.